Clinical Trials Browser

Has announcements × cemiplimab × Clear all

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 3 FDA

Cutaneous Squamous Cell Carcinoma

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Completed

138 enrolled 21 charts 2 FDA

Carcinoma, Basal Cell

NCT03409614 2025-03-13

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

790 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung